Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Ciraparantag for haemorrhage in patients receiving new oral anticoagulants. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Ciraparantag is a new drug to treat bleeding in people taking new oral anticoagulants (NOACs). Anticoagulants are medicines which are given to people to thin the blood and prevent blood clots. Anticoagulation can become a problem when patients experience major bleeding, have a traumatic injury or require emergency surgery. There are currently no licensed treatments that can quickly reverse the effects of NOACs in an emergency. Indexing Status Subject indexing assigned by CRD MeSH Anticoagulants; Hemorrhage; Humans Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016001031 Date abstract record published 11/10/2016 |
